Pulmonary embolism

Factor XI and Factor XII inhibitors

Active trials are underway testing various agents which target Factor XI or Factor XII with different mechanisms of action, and for therapeutic and prophylactic indications. These agents have the potential to be associated with a lower risk of bleeding compared to presently available therapies.[286]Xia Y, Hu Y, Tang L. Factor XIa inhibitors as a novel anticoagulation target: recent clinical research advances. Pharmaceuticals (Basel). 2023 Jun 11;16(6):866. https://pmc.ncbi.nlm.nih.gov/articles/PMC10300994 http://www.ncbi.nlm.nih.gov/pubmed/37375813?tool=bestpractice.com [287]Tashchilova A, Podoplelova N, Sulimov A, et al. New blood coagulation factor XIIa inhibitors: molecular modeling, synthesis, and experimental confirmation. Molecules. 2022 Feb 12;27(4):1234. https://pmc.ncbi.nlm.nih.gov/articles/PMC8876603 http://www.ncbi.nlm.nih.gov/pubmed/35209023?tool=bestpractice.com